CMS Halts New Medicare Home‑Health and Hospice Enrollment, Defers $1.3B to California

Context On May 13 2026 the Centers for Medicare & Medicaid Services announced a nationwide moratorium on new Medicare enrollment for home‑health agencies and hospice providers. The agency cites these sectors as high‑risk for fraudulent billing and says the pause will allow stronger program‑integrity work, including more targeted investigations and expanded use of data‑analytics tools. Currently enrolled providers may continue to serve beneficiaries without interruption.

Key Facts - The moratorium lasts six months and may be renewed in additional six‑month increments if CMS deems it necessary. - CMS will defer $1.3 billion in federal Medicaid payments to California during the review period. - HHS published a proposed rule that would permit employer‑sponsored plans to cover fertility treatments; the public comment window closes July 13 2026. - FDA Commissioner Marty Makary resigned effective immediately; Deputy Commissioner for Food Kyle Diamantas was named acting commissioner pending a permanent appointment.

What It Means For patients, the enrollment freeze means new home‑health or hospice agencies cannot begin billing Medicare until the moratorium lifts, potentially limiting provider choice in some areas. Existing patients should see no change in service delivery. For providers, the pause signals heightened scrutiny; CMS plans to deploy advanced analytics to flag suspicious billing patterns, a move based on internal data that show a correlation between rapid ownership changes and fraud risk, though no randomized trial has tested the moratorium’s effect. States may follow CMS’s lead and consider similar holds for Medicaid programs. The fertility‑benefit rule, if finalized, could expand access to assisted‑reproduction services for workers covered by employer plans, though the final shape depends on public feedback and any subsequent legal challenges. The FDA leadership shift may influence upcoming decisions on drug approvals and food‑safety policies, but the agency’s core processes remain staffed by career officials.

To watch next: whether CMS extends the moratorium beyond six months, the outcome of fraud investigations in California and other states, the final version of the HHS fertility‑benefit rule after the July 13 comment period, and how the acting FDA commissioner navigates pending regulatory initiatives.